Avon licensing deal
This article was originally published in The Rose Sheet
Executive Summary
Beauty firm signs non-exclusive worldwide licensing agreement with drug manufacturer Alteon for use of a patented anti-aging technology in Avon's Anew Alternative Intensive Age Treatment, according to Alteon. The compound, 2-amino-4, 5-dimethylthiazole HBr, improves skin wrinkles and elasticity, Alteon claims. Under the agreement, company will receive a "modest up-front payment and annual license payments" as long as the Anew formula contains the licensed compound, firm adds. Anew Alternative will join Avon's comprehensive Anew anti-aging range, sales of which grew 27% to about $600 mil. in 2004 (1"The Rose Sheet" Feb. 7, 2005, p. 3)...